التفاصيل البيبلوغرافية
| العنوان: |
Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. |
| المؤلفون: |
Senabre-Gallego, José Miguel, Santos-Ramírez, Carlos, Santos-Soler, Gregorio, Salas-Heredia, Esteban, Sánchez-Barrioluengo, Mabel, Barber, Xavier, Rosas, José |
| المصدر: |
Patient Preference & Adherence; 2013, Vol. 7, p961-972, 12p |
| مصطلحات موضوعية: |
ETANERCEPT, ANKYLOSING spondylitis treatment, TUMOR necrosis factors, PHARMACOKINETICS, PSORIASIS, UVEITIS, MAGNETIC resonance imaging, CONGESTIVE heart failure |
| مستخلص: |
To date, anti-tumor necrosis factor alfa (anti-TNF-ϰ) therapy is the only alternative to nonsteroidal anti-inflammatory drugs for the treatment of ankylosing spondylitis. Etanercept is a soluble TNF receptor, with a mode of action and pharmacokinetics different to those of antibodies and distinctive efficacy and safety. Etanercept has demonstrated efficacy in the treatment of ankylosing spondylitis, with or without radiographic sacroiliitis, and other manifestations of the disease, including peripheral arthritis, enthesitis, and psoriasis. Etanercept is not efficacious in inflammatory bowel disease, and its efficacy in the treatment of uveitis appears to be lower than that of other anti-TNF drugs. Studies of etanercept confirmed regression of bone edema on magnetic resonance imaging of the spine and sacroiliac joint, but failed to reduce radiographic progression, as do the other anti-TNF drugs. It seems that a proportion of patients remain in disease remission when the etanercept dose is reduced or administration intervals are extended. Etanercept is generally well tolerated with an acceptable safety profile in the treatment of ankylosing spondylitis. The most common adverse effect of etanercept treatment is injection site reactions, which are generally self-limiting. Reactivation of tuberculosis, reactivation of hepatitis B virus infection, congestive heart failure, demyelinating neurologic disorders, hematologic disorders like aplastic anemia and pancytopenia, vasculitis, immunogenicity, and exacerbation or induction of psoriasis are class effects of all the anti-TNF drugs, and have been seen in patients with ankylosing spondylitis. However, etanercept is less likely to induce reactivation of tuberculosis than the other anti-TNF drugs and it has been suggested that etanercept might be less immunogenic, especially in ankylosing spondylitis. Acute uveitis, Crohn's disease, and sarcoidosis are other adverse events that have been rarely associated with etanercept therapy in patients with ankylosing spondylitis. [ABSTRACT FROM AUTHOR] |
|
Copyright of Patient Preference & Adherence is the property of Dove Medical Press Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder